Oncolytics Biotech Stock Total Debt
| ONCY Stock | USD 0.94 0.01 1.05% |
Oncolytics Biotech fundamentals help investors to digest information that contributes to Oncolytics Biotech's financial success or failures. It also enables traders to predict the movement of Oncolytics Stock. The fundamental analysis module provides a way to measure Oncolytics Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncolytics Biotech stock.
Total Debt To Capitalization is likely to rise to 0.01 in 2024. Oncolytics | Total Debt |
Oncolytics Biotech Company Total Debt Analysis
Oncolytics Biotech's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Oncolytics Biotech Total Debt | 423 K |
Most of Oncolytics Biotech's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncolytics Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Oncolytics Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Oncolytics Biotech is extremely important. It helps to project a fair market value of Oncolytics Stock properly, considering its historical fundamentals such as Total Debt. Since Oncolytics Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oncolytics Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oncolytics Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Oncolytics Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Oncolytics Biotech has a Total Debt of 423 K. This is 99.98% lower than that of the Biotechnology sector and 99.87% lower than that of the Health Care industry. The total debt for all United States stocks is 99.99% higher than that of the company.
Oncolytics Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncolytics Biotech's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncolytics Biotech could also be used in its relative valuation, which is a method of valuing Oncolytics Biotech by comparing valuation metrics of similar companies.Oncolytics Biotech is currently under evaluation in total debt category among its peers.
Oncolytics Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Oncolytics Biotech from analyzing Oncolytics Biotech's financial statements. These drivers represent accounts that assess Oncolytics Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Oncolytics Biotech's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 136.7M | 122.5M | 94.0M | 128.1M | 118.2M | 137.3M | |
| Enterprise Value | 123.1M | 91.6M | 53.4M | 116.8M | 83.7M | 118.0M |
Oncolytics Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Oncolytics Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Oncolytics Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Oncolytics Biotech's value.| Shares | Bmo Capital Markets Corp. | 2024-06-30 | 37.4 K | Virtu Financial Llc | 2024-06-30 | 27.4 K | Brave Asset Management Inc | 2024-09-30 | 25 K | Newman Dignan & Sheerar Inc | 2024-09-30 | 22 K | Financial Advisory Corp /ut/ /adv | 2024-09-30 | 20.6 K | Lpl Financial Corp | 2024-09-30 | 20.5 K | Head & Associates, Llc | 2024-09-30 | 17.4 K | C2p Capital Advisory Group Llc Dba Prosperity Capital Advisors | 2024-09-30 | 15 K | Ausdal Financial Partners Inc | 2024-09-30 | 14 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 277 K | Seeds Investor Llc | 2024-09-30 | 189.9 K |
Oncolytics Fundamentals
| Return On Equity | -1.38 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 60.06 M | ||||
| Shares Outstanding | 77.07 M | ||||
| Shares Owned By Insiders | 3.81 % | ||||
| Shares Owned By Institutions | 1.76 % | ||||
| Number Of Shares Shorted | 2.81 M | ||||
| Price To Earning | (2.06) X | ||||
| Price To Book | 11.35 X | ||||
| EBITDA | (33.71 M) | ||||
| Net Income | (27.75 M) | ||||
| Cash And Equivalents | 32.36 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 423 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 10.42 X | ||||
| Book Value Per Share | 0.37 X | ||||
| Cash Flow From Operations | (28.45 M) | ||||
| Short Ratio | 3.51 X | ||||
| Earnings Per Share | (0.26) X | ||||
| Target Price | 6.97 | ||||
| Beta | 1.51 | ||||
| Market Capitalization | 73.54 M | ||||
| Total Asset | 38.82 M | ||||
| Retained Earnings | (446 M) | ||||
| Working Capital | 33.94 M | ||||
| Current Asset | 14.39 M | ||||
| Current Liabilities | 2.91 M | ||||
| Net Asset | 38.82 M |
About Oncolytics Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncolytics Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncolytics Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncolytics Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.